GLSI
Greenwich·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 1
Bearish signal 2
Ample Liquidity
Significant Net Income Decline
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About GLSI
Greenwich Lifesciences, Inc.
A clinical-stage biopharmaceutical company that develops breast cancer immuno therapies to prevent the recurrence of breast cancer following surgery
Pharmaceutical
08/29/2006
09/25/2020
NASDAQ Stock Exchange
4
12-31
Common stock
3992 Bluebonnet Dr, Building 14, Stafford, TX 77477
--
Greenwich LifeSciences, Inc., established on August 29, 2006, is a Delaware corporation. The company, a biopharmaceutical company, is developing GP 2, an immunotherapy designed to prevent postoperative breast cancer recurrence.
Company Financials
EPS
GLSI has released its 2025 Q3 earnings. EPS was reported at -0.3, versus the expected -0.36, beating expectations. The chart below visualizes how GLSI has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
